To the full analysis
Buyback calculator for Aquestive Therapeutics
Aquestive Therapeutics stock: key metrics
AQSTAquestive Therapeutics had an operating margin of −156.4% and a return on invested capital (ROIC) of −53.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | 68.4% | −1.6% | −18.5% |
| 2017 | 70.4% | −0.2% | −13.4% |
| 2018 | 68.9% | −72.6% | −91.0% |
| 2019 | 61.3% | −100.1% | −125.9% |
| 2020 | 71.7% | −93.6% | −121.7% |
| 2021 | 70.5% | −68.2% | −138.8% |
| 2022 | 59.3% | −88.2% | −114.1% |
| 2023 | 58.8% | −29.9% | −15.6% |
| 2024 | 69.0% | −53.5% | −76.7% |
| 2025 | 61.5% | −156.4% | −188.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | 54.6% | −5.6% | −24.4% |
| 2017 | 33.8% | −1.3% | −20.7% |
| 2018 | −100.0% | −89.6% | −70.7% |
| 2019 | 200.0% | −70.3% | −84.4% |
| 2020 | 115.0% | −65.0% | −88.7% |
| 2021 | 85.9% | −63.4% | −100.0% |
| 2022 | 45.9% | −84.9% | −95.3% |
| 2023 | 7.4% | −31.7% | −13.7% |
| 2024 | 73.4% | −39.9% | −43.5% |
| 2025 | 200.0% | −53.2% | −52.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.